Clinical Scenario A five-year-old...

Clinical Scenario

A five-year-old girl not aways with a 4-by-6-cm area of honey-crusted meeting papules of four days' duration upon her face. Your diagnosis is impetigo.

Clinical Question

Which treatments for impetigo are mostly effective?

Evidence-Based Answer

The topical antibiotic mupirocin is as effective or possibly more effective than oral treatment in patients with limited disease.

For practical reasons, oral antibiotics of the like kind as penicillins, cephalosporins, and macrolides frequently are used in patients with extensive disease, nevertheless there is insufficient evidence to determine whether topical or systemic antibiotics are more effective. Limited evidence does not support the use of disinfectants.

Practice Pointers

Impetigo is a contagious superficial skin infection principally frequently encountered in children, with a peak incidence between the ages of sum of two units and six years. (1) In fact, impetigo is the most numerous common skin infection in children. (2)

Causative agents include clump A a-hemolytic streptococci (GABHS) and Staphylococcus aureus. The differential diagnosis of nonbullous impetigo includes shingles, polar sores, cutaneous fungal infections, and eczema. The differential diagnosis of bullous impetigo includes thermal calcines blistering disorders, and Stevens-Johnson syndrome Complications of the like kind as cellulitis, lymphangitis, and septicemia are rare and deduction from spread of the infection. The infection is transmitted via direct contact with the lesion.

Because trials in this review included children and adults, the average age of trial participants was frequently older than that of the typical impetigo patient. In all however two studies, investigators performed bacteriologic investigations to confirm the diagnosis. The main issue measured in this review was the clinical restorative rate after one week of treatment. "Clinical cure" included specific as assessed by the investigator (which was ofttimes not defined and sometimes included the pair improvement and cure after varying long durations of treatment) and relief of symptoms as assessed by means of the participants. Length of follow-up varied widely in individual studies and sometimes was not specified. Many of the trials studied the same treatment for multiple diseases and therefore had not many cases of impetigo.

Although impetigo is notion to be a self-limiting condition, studies upon its natural history do not exist and are ethically unfeasible. Disinfectants like as povidone-iodine and chlorhexidine have been inadequately studied and have not been compared with placebo. At this time, there is no evidence to support the use of disinfectants as either single or supplementary treatment for impetigo; this is an area for events to come research.

Antibiotics are the mainstay of therapy. Physicians first must decide forward a route of administration, either topical or systemic, and then upon a specific drug. If the area of affected skin is limited, mupirocin is an effective topical therapy; it was more effective than the other topical antibiotics studied (i.e., neomycin, bacitracin, polymyxin B and gentamicin). There is insufficient evidence to determine whether oral antibiotics are better than topical agents in patients with more extensive disease, although there are obvious practical reasons to pick out oral agents if large amounts of skin are involved. Antibiotic categories to consider include penicillins, cephalosporins, and macrolides. Oral antibiotics have significantly more side tenors especially gastrointestinal effects, than topical agents.

RELATED ARTICLE: Cochrane Abstract.

Background. Impetigo is a usual superficial bacterial skin infection that is combated most frequently in children. There is no standard therapy, and guidelines for treatment differ widely. Treatment options include oral and topical antibiotics, as well as disinfectants.

Objectives. To assess the validitys of treatments for impetigo, including waiting for natural resolution.

Search Strategy. The authors3 searched the Skin arrange Specialized Trials Register (March 2002) Cochrane Central Register of Controll Trials (CENTRAL, Issue 1 2002) the National Research Register (2002) MEDLINE (from 1966 to January 2003) EMBASE (from 1980 to March 2000) and LILACS (November 2001) They hand searched the Yearbook of Dermatology (1938 to 1966) and the Yearbook of remedy Therapy (1949 to 1966), referr to article intimation lists, and contacted pharmaceutical companies.

Selection Criteria. Randomized controll trials of treatments for nonbullous and bullous, primary and secondary impetigo were selected

Data Collection and Analysis. All gradations in data collection were done by the agency of two independent reviewers. Quality assessments and data collection were performed in separate stages.

Primary deductions A total of 57 trials of 3533 participants was included; 20 oral and 18 topical treatments were studied. Topical antibiotics showed better restorative rates than placebo (pooled unevens ratio [OR], 6.49; 95 percent confidence interval [CI], 393 to 1073) and no topical antibiotic was superior to another (pool OR of mupirocin versus fusidic acid, 176; 95 percent CI, 069 to 216) Topical mupirocin was superior to oral erythromycin (pool OR, 122; 95 percent CI, 105 to 297) In chiefly other comparisons, topical and oral antibiotics did not point out to significantly different cure rates, nor did principally trials comparing oral antibiotics. Penicillin was inferior to erythromycin and cloxacillin, and there is little evidence that use of disinfectant solutions improved impetigo. The reported number of side meanings was low. Oral antibiotic treatment caused more side events especially gastrointestinal effects, than topical treatment did.